Amgen Inc (AMGN)

281.99
-0.63(-0.22%)
After Hours
281.70
-0.29(-0.10%)
- Real-time Data
  • Volume:
    2,133,939
  • Day's Range:
    279.68 - 283.38
  • 52 wk Range:
    198.64 - 296.67

AMGN Overview

Prev. Close
282.62
Day's Range
279.68-283.38
Revenue
26.19B
Open
283.38
52 wk Range
198.64-296.67
EPS
12.54
Volume
2,133,939
Market Cap
150.46B
Dividend (Yield)
7.76
(2.75%)
Average Volume (3m)
2,796,075
P/E Ratio
23.01
Beta
0.64
1-Year Change
40.54%
Shares Outstanding
533,579,206
Next Earnings Date
02 Feb 2023
What is your sentiment on Amgen?
or
Market is currently closed. Voting is open during market hours.

Amgen Inc News

Amgen Inc Analysis

Amgen Inc Company Profile

Amgen Inc Company Profile

Employees
24200

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Read More

Analyst Price Target

Average261.68 (-7.20% Downside)
High325
Low180
Price281.99
No. of Analysts29
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuySellSellBuyStrong Buy
Technical IndicatorsBuySellStrong SellStrong SellStrong Buy
SummaryBuySellStrong SellNeutralStrong Buy
  • Strong buy
    0